Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Most stock quote data provided by BATS. An Overall Rank of 89 means that our comprehensive methodology rates Bioxcel Therapeutics Inc above 89% of stocks. Want to see which stocks are moving? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
BioXcel Therapeutics employs 18 workers across the globe.Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. See what's happening in the market right now with MarketBeat's real-time news feed.
All rights reserved. Since then, BTAI stock has increased by 108.5% and is now trading at $61.48.
Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:One share of BTAI stock can currently be purchased for approximately $47.90.BioXcel Therapeutics does not have a long track record of dividend growth.Earnings for BioXcel Therapeutics are expected to decrease in the coming year, from ($2.96) to ($2.98) per share.BioXcel Therapeutics has a market capitalization of $968.11 million.
View real-time stock prices and stock quotes for a full financial overview. BioXcel Therapeutics, Inc Stock Price Forecast, "BTAI" Predictons for2020 Get the latest BioXcel Therapeutics Inc BTAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. View which stocks have been most impacted by Coronavirus. What this means: Bioxcel Therapeutics Inc (BTAI) gets a very positive evaluation from InvestorsObserver's ranking system. BTAI Stock Analysis Overview . Learn about financial terms, types of investments, trading strategies and more.BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI. The average price target is $123.00 with a high forecast of $200.00 and a low forecast of $63.00. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN.
Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com. View BioXcel Therapeutics Inc BTAI investment & stock information. With a 5-year investment, the revenue is expected to be around +519.17%. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.Shares of BTAI can be purchased through any online brokerage account. BTAI | Complete BioXcel Therapeutics Inc. stock news by MarketWatch. Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. BioXcel Therapeutics, Inc quote is equal to 53.280 USD at 2020-07-09. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. View which stocks are hot on social media with MarketBeat's trending stocks report.Only 9.40% of the stock of BioXcel Therapeutics is held by insiders.In the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Learn everything you need to know about successful options trading with this three-part video course.BioXcel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.BioXcel Therapeutics does not currently pay a dividend.Only 29.71% of the stock of BioXcel Therapeutics is held by institutions.The P/E ratio of BioXcel Therapeutics is -20.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Identify stocks that meet your criteria using seven unique stock screeners.
Find real-time BTAI - BioXcel Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. All rights reserved. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Disclaimer. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Who this matters to: Overall Ranking is a comprehensive evaluation. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Factset: FactSet Research Systems Inc.2019. View our full suite of financial calendars and market data tables, all for free.Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.Receive a free world-class investing education from MarketBeat. According to analysts' consensus price target of $102.00, BioXcel Therapeutics has a potential upside of 112.9% from its current price of $47.90.Looking for new stock ideas? Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Your current $100 investment may be up to $619.17 in 2025.